Training the next generation

CALIFORNIA HIGH SCHOOL, UNDERGRADUATE AND GRADUATE STUDENTS WILL BECOME TOMORROW'S STEM CELL SCIENTISTS.

CIRM has programs to bring high school, undergraduate and master's students—many from economically challenged backgrounds—into stem cell science careers.

Our programs also train graduate and post-graduate students to run their own stem cell labs.

These students will be tomorrow's stem cell scientists, continuing California's leadership in developing therapies for incurable disease and injury.




"Our programs train California's diverse young people to build the state's stem cell workforce and develop the next generation of new therapies"

BERTRAM LUBIN, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND, CIRM BOARD MEMBER

CIRM Research Funding

- Funding committed in 2012: \$307M
- Total Funding commitment: \$1,777M
- Awards granted in 2012: 54
- Total awards granted: 586




Learn more about where our funding goes: www.cirm.ca.gov/ grants

Disease Category

By award number

- Neurological disorders
- Heart disease
- Blood/immune disorders
- Cancer
- Sensory organs
- Bone/cartilage disorders
- Muscular disorders
- Diabetes
- GI/liver disease
- Reproductive disorders
- Other disorders



Stem Cell Type Funded

By award number

- Embryonic
- Reprogrammed iPS cell
- Adult
- Cancer
- Other
- Direct reprogramming
- SCNT





210 King Street, San Francisco CA 94107
Tel 415. 396. 9100 Fax 415. 396. 9141 info@cirm.ca.gov www.cirm.ca.gov



Letter from the Chairman

Jonathan Thomas, J.D., Ph.D. CELEBRATING SCIENCE



My excitement about this year's progress was neatly summarized by a "Celebration of Science" event I attended in Washington D.C.. It highlighted the inexorable march of scientific achievement over the past decades and the role biology plays in improving the world. In creating CIRM, the voters of California have made the state the epicenter of the regenerative medicine revolution promising to accelerate that historic march toward new and better therapies.

Our expanding portfolio of projects is funding 60 institutions and companies looking to conquer no fewer than 31 currently incurable diseases or conditions, aiming to deliver on the technology's promise to all those patients in desperate need of therapies or cures. A principal goal going forward is to connect our groundbreaking scientists with biotechnology and pharmaceutical companies, which could provide additional funds and ultimately bring cellular therapies to market. This process is well underway, with several CIRM-funded clinical trials expecting to enroll their first patients this year.

While we can't guarantee success, we feel with each passing year that we're getting closer to profound results that would have an enormous impact on the citizens of California, the nation, and the world.

"We ended the year with 77 projects in the later stages of translation for clinical use."

ALAN TROUNSON PH.D. PRESIDENT

"We congratulate
Dr. Shinya Yamanaka on his 2012 Nobel Prize
for pioneering work in stem cell research."
JONATHAN THOMAS, J.D., PH.D., CHAIRMAN

Letter from the President

Alan Trounson, Ph.D.

ENTERING A SECOND PHASE WITH THERAPIES IN OUR SIGHT



We adopted a revised strategic plan this year that refines and re-enforces our founding goals: developing therapies to relieve human suffering. That plan reacts to the rapid evolution of stem cell science, incorporates more closely the biotechnology sector and positions the agency to further accelerate the path to therapies.

Our funding actions this year make clear we are already heeding the goals laid out in our new strategic plan. We ended the year with 77 projects in the later stages of translation for clinical use. This represents an 80 percent increase in these clinically directed projects in just one year.

We closed out the year with a round of grants designed to further hasten the pace to the clinic. We made a dozen New Faculty awards to junior faculty who are both physicians and scientists and understand the lab and the clinic. They are often key to moving therapies forward.

The year also saw another round of Basic Biology awards. Those fund transforming new ideas that are changing the stem cell field and will eventually result in novel approaches for the therapies that motivated all those who supported the creation of CIRM.



Stories of Hope

DIANA SOUZA HAD HER SEVERELY FRACTURED ARM REPAIRED WITH A STEM CELL THERAPY

See more stories of hope online: www.cirm.ca.gov/hope


"I like my lifestyle and I like what I do.
For me, this was a miracle."
DIANA SOUZA, BONE FRACTURE

Progress Toward Therapies

CIRM-FUNDED PROJECTS NEARING PATIENTS

CIRM funds all phases of research from basic science that produces breakthrough ideas all the way through to testing whether potential therapies are safe in patients. So far, 77 of our projects in 31 disease areas are in various stages of working toward clinical trials.

Therapy Development Pipeline



Accomplishments: Putting California Funds to Work

- Funds leveraged from private donors/institutions: \$884M
- Follow-on research funds from NIH, etc: \$379M
- Funds leveraged from collaborative partners: \$75M
- Job years forecast by 2014: 38,000
- Tax revenues forecast by 2014: \$286M

For more information on these successes and for a full report on the CIRM financials see the annual report online: www.cirm.ca.gov/ 2012AnnualReport